# reload+after+2024-01-20 21:47:48.521624
address1§6000 Shoreline Court
address2§Suite 300
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 243 6300
fax§650 243 6301
website§https://www.veracyte.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
fullTimeEmployees§787
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Marc A. Stapley', 'age': 53, 'title': 'CEO & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 1253000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Rebecca  Chambers', 'age': 45, 'title': 'Executive VP & CFO', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 772410, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Annie  McGuire', 'age': 42, 'title': 'Executive VP, General Counsel & Chief People Officer', 'yearBorn': 1981, 'fiscalYear': 2022, 'totalPay': 633652, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jonathan  Wygant', 'age': 52, 'title': 'VP & Chief Accounting Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steven  French', 'title': 'Senior VP & Chief Information Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Phillip G. Febbo M.D.', 'age': 57, 'title': 'Chief Scientific & Medical Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tracy  Morris', 'title': 'Vice President of Global Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Brainin', 'age': 52, 'title': 'Executive VP & Chief Business Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Fabienne  Hermitte Ph.D.', 'title': 'Senior Vice President of Global Quality & Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. John  Leite Ph.D.', 'title': 'Chief Commercial Officer for CLIA Business', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§2
compensationRisk§7
shareHolderRightsRisk§4
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.803
priceToSalesTrailing12Months§5.476663
currency§USD
dateShortInterest§1702598400
forwardEps§-0.27
exchange§NGM
quoteType§EQUITY
shortName§Veracyte, Inc.
longName§Veracyte, Inc.
firstTradeDateEpochUtc§1383139800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§0ed080f4-1811-3c23-a041-70d21c58c2b4
gmtOffSetMilliseconds§-18000000
targetHighPrice§37.0
targetLowPrice§23.0
targetMeanPrice§32.33
targetMedianPrice§34.5
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§4.222
grossMargins§0.6784
ebitdaMargins§0.01202
trailingPegRatio§None
